Edwards Lifesciences Corp

Edwards operates globally and reports sales across the United States, Europe, Japan, and Rest of World. The United States is its largest market, and Europe is the next most important region, while Japan and other international markets add diversification but also expose the company to reimbursement, regulatory, and procedural timing differences. The company also notes that third-quarter sales are typically softer because summer vacation schedules reduce procedure volumes in the U.S. and Europe.

The company depends on successful innovation, clinical trial outcomes, and physician adoption, so product setbacks can directly slow growth. It also faces manufacturing, logistics, supplier, reimbursement, litigation, and cybersecurity risks typical of regulated medical device businesses, with international exposure adding tax and regulatory complexity. Because procedures are hospital-based and elective timing matters, seasonality and public health disruptions can also affect quarterly results.